MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Contact Us

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

ASCO-GU 2023

2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium - February 16-18, 2023 / San Francisco, CA and Virtual

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

READY: REAl-World Data from an Italian Compassionate Use Program of Avelumab First-Line Maintenance Treatment for locallY Advanced or Metastatic Urothelial Carcinoma (la/mUC) (includes PLS)

Antonuzzo | Poster #469

Full Analysis from AVENANCE: A Real-World Study of Avelumab First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Barthélémy | Poster #471

Baseline Characteristics from a Retrospective, Observational, US-Based, Multicenter, Real-World Study of Avelumab First-Line Maintenance in Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC) (PATRIOT-II) (includes PLS)

Grivas | Poster #465

Real-World Treatment Patterns and Sequencing in Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) in the US

Kearney | Poster #572

Assessment of Treatment Patterns and Real-World Outcomes Following Changes in the Treatment Paradigm for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC) in the US

Kirker | Poster #468

A UK Real-World Observational Study of Avelumab + Axitinib (A + Ax) in Advanced Renal Cell Carcinoma (aRCC): 24-Month Interim Results (includes PLS)

Nathan | Poster #631

Treatment Patterns, Indicators of Receiving Systemic Treatment, and Clinical Outcomes in Metastatic Urothelial Carcinoma: A Retrospective Analysis of Real-World Data in Germany

Niegisch | Poster #464

Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up from the JAVELIN Bladder 100 Trial in Subgroups Defined by 1L Chemotherapy Regimen and Analysis of Overall Survival from Start of 1L Chemotherapy (includes PLS)

Sridhar | Poster #508

SPADE: Design of a Real-World Observational Study of Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma in the Asia-Pacific Region

Su | Poster #577

C-Reactive Protein (CRP) as a Predictive Marker for Outcomes with Avelumab + Axitinib (A + Ax) in Patients with Poor-Risk Advanced Renal Cell Carcinoma (aRCC): Exploratory Analysis from JAVELIN Renal 101 (includes PLS)

Tomita | Poster #670

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: